Data on 1,020 metformin-treated type 2 diabetes patients revealed those who took canagliflozin attained lower fasting plasma glucose and showed greater improvements in glycemic control, body weight and blood pressure at 52 weeks than those who either took sitagliptin or placebo followed by sitagliptin. However, canagliflozin was linked to higher rates of genital mycotic infections and adverse events related to osmotic diuresis compared with the other treatments, researchers reported at the 73rd Scientific Sessions of the American Diabetes Association.

Related Summaries